Jack Geltosky, Ph.D. Joins Enzon's Board of Directors

BRIDGEWATER, NJ – May 28, 2008 – Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that Dr. Jack Geltosky has been appointed to the Company’s Board of Directors.

Dr. Geltosky is currently the Senior Vice President of Business Development, Life Sciences for Arizona Technology Enterprises. He has more than 20 years of pharmaceutical experience and has extensive expertise in developing business strategies for commercialization of proprietary, breakthrough technologies across many therapeutic areas. He has worked for pharmaceutical companies such as Bristol-Myers Squibb, Smithkline Beecham Pharmaceuticals and Johnson & Johnson, where he collaborated closely with R&D and Marketing. 

“We are pleased to have Jack Geltosky join our Board,” said Jeffrey H. Buchalter, Enzon’s chairman and chief executive officer. “Dr. Geltosky is a demonstrated leader with broad industry experience that will complement the current expertise of the Enzon Board.”
 
Dr. Geltosky earned a Bachelor of Science degree in Chemistry from Memphis State University, graduating magna cum laude, and he earned his Ph.D. in Biochemistry from California Institute of Technology. Additionally, he completed his NIH Postdoctoral Fellowship and American Cancer Society Fellowship, California Division.

About Enzon

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development, manufacturing, commercialization of important medicines for patients with cancer and other life-threatening conditions. Enzon has a portfolio of four marketed products, Oncaspar®, DepoCyt®, Abelcet® and Adagen®. The Company's drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform used to create product candidates with benefits such as reduced dosing frequency and less toxicity. Enzon's PEGylation technology was used to develop two of its products, Oncaspar and Adagen, and has created a royalty revenue stream from licensing partnerships for other products developed using the technology. Enzon also engages in contract manufacturing for several pharmaceutical companies to broaden the Company's revenue base. Further information about Enzon and this press release can be found on the Company's web site at www.enzon.com.

SOURCE: Enzon Pharmaceuticals, Inc.

Enzon Pharmaceuticals, Inc.
Craig Tooman
EVP, Finance and Chief Financial Officer
908-541-8777